FGF21 and obesity due to melanocortin 4 receptor deficiency: A randomized, placebo-controlled, double-blind proof-of-concept trial conducted in patients with obesity and T2DM revealed that LY2405319 (LY), an investigational FGF21 variant deemed suitable for early-phase clinical development, demonstrated significant improvements in dyslipidemia.